肝硬化患者丙型肝炎病毒感染的治疗及终末期肝病模型预测价值:Hepa-C登记数据分析
西班牙Hepa-C登记的多中心回顾性非干预研究分析了843例肝硬化患者接受无干扰素直接抗病毒药物治疗的效果与安全性,总体持续病毒学应答12周(SVR12)率90%,CTP A级与B/C级患者SVR12率分别为94%与78%,严重不良事件在B/C级更常见,基线MELD评分(截断值18)是生存的最佳预测指标。
要点
- 肝硬化患者接受无干扰素DAA方案总体SVR12率为90%。
- CTP B/C级患者SVR12率低于A级(78% vs 94%),复发率更高(14% vs 4%)。
- 基线MELD评分≥18可能有助于识别并发症风险较高的患者。
核心结论
- 失代偿期肝硬化患者接受DAA治疗应答率较低且严重不良事件更多。
- 在此背景下,MELD评分≥18可能帮助临床医生识别并发症风险较高的患者并个体化治疗决策。
研究设计与样本
- 西班牙Hepa-C登记的多中心、回顾性、非干预性研究,纳入843例肝硬化患者(CTP A级564例,CTP B/C级175例),所有当前获批方案均登记。
- 排除治疗期间或完成治疗后12周内接受肝移植的患者。
主要发现
- 总体SVR12率为90%。
- CTP A级与CTP B/C级患者SVR12率分别为94%与78%,复发率分别为4%与14%(均P < 0.001)。
- 严重不良事件在CTP B/C级与A级患者中分别为50%与12%(P < 0.001)。
- 新发失代偿是最常见的严重不良事件(总体7%)。
- 研究期间死亡率为16/843(2%),CTP B/C级与A级患者分别为6.4%与0.9%(P < 0.001)。
关键数值与推荐
- 基线MELD评分单独(截断值18)是生存的最佳预测指标。
临床怎么用
- 失代偿期肝硬化患者接受DAA治疗应答率较低且严重不良事件更多。
- MELD评分≥18可能帮助临床医生识别并发症风险较高的患者并个体化治疗决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Direct-acting antiviral agents (DAAs) are highly effective and well tolerated in patients with chronic hepatitis C virus infection, including those with compensated cirrhosis. However, fewer data are available in patients with more advanced liver disease. Our retrospective, noninterventional, national, multicenter study in patients from the Spanish Hepa-C registry investigated the effectiveness and safety of interferon-free DAA regimens in patients with advanced liver disease, including those with decompensated cirrhosis, in routine practice (all currently approved regimens were registered). Patients transplanted during treatment or within 12 weeks of completing treatment were excluded. Among 843 patients with cirrhosis (Child-Turcotte-Pugh [CTP] class A, n = 564; CTP class B/C, n = 175), 90% achieved sustained virologic response 12 weeks after treatment (SVR12). Significant differences in SVR12 and relapse rates were observed between CTP class A and CTP class B/C patients (94% versus 78%, and 4% versus 14%, respectively; both P < 0.001). Serious adverse events (SAEs) were more common in CTP class B/C versus CTP class A patients (50% versus 12%, respectively; P < 0.001). Incident decompensation was the most common serious adverse event (7% overall). Death rate during the study period was 16/843 (2%), significantly higher among CTP class B/C versus CTP class A patients (6.4% versus 0.9%; P < 0.001). Baseline Model for End-Stage Liver Disease (MELD) score alone (cut-off 18) was the best predictor of survival. CONCLUSION: Patients with decompensated cirrhosis receiving DAAs present lower response rates and experience more SAEs. In this setting, a MELD score ≥18 may help clinicians to identify those patients with a higher risk of complications and to individualize treatment decisions. (Hepatology 2017;65:1810-1822).
引用
- Fernández Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. Hepatology. 2017. PMID: 28170112. doi:10.1002/hep.29097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。